Brief: Axovant Gene Therapies Receives Rare Pediatric Disease Designation For Axo-Aav-Gm1 For Gm1 Gangliosidosis

Sio Gene Therapies

09/10/2020 12:04

Oct 9 (Reuters) - Axovant Gene Therapies Ltd  AXGT.O :
    * AXOVANT GENE THERAPIES RECEIVES RARE PEDIATRIC DISEASE
DESIGNATION FOR AXO-AAV-GM1 FOR GM1 GANGLIOSIDOSIS
    * AXOVANT GENE THERAPIES - EXPECTS TO INITIATE HIGH DOSE
COHORT
WHICH INCLUDES INFANTILE AND JUVENILE  PATIENTS IN SECOND HALF
OF 2020
    * AXOVANT GENE THERAPIES - ON-TRACK TO REPORT 6-MONTH STAGE
1 DATA
FROM LOW DOSE JUVENILE COHORT BY Q4 OF 2020

Source text for Eikon:  ID:nGNX1s2FW4 
Further company coverage:  AXGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))